AN OPEN-LABEL, SINGLE ARM, LONG TERM TRIAL OF SPESOLIMAB TREATMENT IN PATIENTS WITH PALMOPLANTAR PUSTULOSIS (PPP) WHO HAVE COMPLETED PREVIOUS BI SPESOLIMAB TRIALS
- Registry ID
- 1368-0024
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- BOEHRINGER INGELHEIM (CANADA) LTD LTEE
- Start date
- 2020-08-31
- Completion date
- 2023-05-30
- Last update
- 2020-05-28
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH PALMOPLANTAR PUSTULOSIS
- A PROOF-OF-CONCEPT PHASE 2A, DOUBLE-BLIND, 2-ARM TRIAL TO INVESTIGATE
EFFICACY AND SAFETY OF TWICE DAILY DELGOCITINIB CREAM 20 MG/G COMPARED
WITH CREAM VEHICLE DURING A 16-WEEK TREATMENT PERIOD IN ADULT SUBJECTS
WITH MILD TO SEVERE PALMOPLANTAR PUSTULOSIS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIST4721 IN SUBJECTS WITH PALMOPLANTAR PUSTULOSIS
- MULTI-CENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE IIB DOSE-FINDING STUDY TO EVALUATE EFFICACY AND SAFETY OF DIFFERENT SUBCUTANEOUS DOSES OF BI 655130 IN PATIENTS WITH MODERATE TO SEVERE PALMOPLANTAR PUSTULOSIS (PPP)
View on source registry